Dr Daniel Myall
BSc (Hons), PhD
Bioinformatics Manager
New Zealand Brain Research Institute, Christchurch
Senior Research Fellow
, New Zealand Brain Research Institute, Christchurch
Email: daniel.myall@nzbri.org
Phone: 033786083
As the bioinformatics manager at NZBRI I’m responsible both for data management and assisting researchers with statistical analysis. My areas of statistics expertise are biostatistics, Bayesian modelling, multilevel models, and machine learning.
I have been a member of the Christchurch Parkinson’s research group since 2002.
My particular areas of research interest are:
- The epidemiology of Parkinson’s and Multiple Sclerosis.
- Genetic and environmental factors contributing to Parkinson’s disease.
- Developing predictive models of future cognitive decline.
- Electric Vehicles
Current projects I'm working on include:
- Updated epidemiology estimates of Parkinson's in New Zealand
- New Zealand Parkinson's Progression Programme (NZP3)
- New Zealand Parkinson's Environment and Gene Study (NZPEGS)
I am a member of:
Publications
Provided on request for non-commercial personal use by researchers.
2025
(2025). Estimating the seasonal variation in electricity demand of future electric vehicle fleets. Energy, 137089. 10.1016/j.energy.2025.137089
(2025). Goal-directedness deficit in Huntington’s disease. Cognitive, Affective, & Behaviora, 1-14. 10.3758/s13415-025-01313-0
(2025). Magnetic Resonance Imaging as a Readout of CLN5 Gene Therapy Efficacy in Sheep. Brain and Behavior, 15, e70431. 10.1002/brb3.70431
2024
(2024). Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 16(2), e12601.. 10.1002/dad2.12601
(2024). Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis. Brain Sciences, 14(7), 669. 10.3390/brainsci14070669
(2024). Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease. Neurology, 102(12), e209301. 10.1212/WNL.0000000000209301
(2024). Decision cost hypersensitivity underlies Huntington’s disease apathy. Brain, awae296. 10.1093/brain/awae296
(2024). Apathy and Impulsivity Co-Occur in Huntington's Disease. Brain and Behavior, 14: e70061.. 10.1002/brb3.70061
(2024). Disrupted Time Perception Underlies Motivational Disturbances in Huntington’s Disease. Timing & Time Perception, 1(aop), 1-24. 10.1163/22134468-bja10115
(2024). Cholinergic basal forebrain integrity and cognition in Parkinson’s disease: a re-appraisal of MRI evidence. Movement Disorders, 12, 2155-2172. 10.1002/mds.30023
2023
(2023). Clinical outcomes with delayed mechanical thrombectomy: Descriptive analysis and development of a screening tool. European Journal of Neurology, 3, 671-677. 10.1111/ene.15658
(2023). Bridging Big Data: Procedures for Combining Non-equivalent Cognitive Measures from the ENIGMA Consortium. bioRxiv, 2023-01. 10.1101/2023.01.16.524331
(2023). Multiple sclerosis mortality in New Zealand: a nationwide prospective study. Journal of Neurology Neurosurgery & Psychiatry, jnnp-2022-33058. 10.1136/jnnp-2022-330582
(2023). The New Zealand Parkinson’s Progression Programme. Journal of the Royal Society of New Zealand, 53, 466-488. 10.1080/03036758.2022.2111448
(2023). Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis. Brain Communications, 5(1). 10.1093/braincomms/fcac339
2022
(2022). Level I PD‐MCI using global cognitive tests and the risk for Parkinson’s disease dementia. Movement Disorders Clinical Practice, 9(4), 479-483. 10.1002/mdc3.13451
(2022). Reply to: “An Exponential Rather Than Multistep Model of Parkinson’s Disease Pathogenesis”. Movement Disorders, 37(5), 1107. 10.1002/mds.28989
2021
(2021). Automated segmentation of substantia nigra and red nucleus using quantitative susceptibility mapping images: application to Parkinson’s disease. Computers & Electrical Engineering, 91, 107091. 10.1016/j.compeleceng.2021.107091
(2021). Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand. The New Zealand Medical Journal, 134, 44-51.
(2021). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. Movement Disorders Clinical Practice, 8, 390-399. 10.1002/mdc3.13151
(2021). A multi-step model of Parkinson’s disease pathogenesis. Movement Disorders, 36, 2530-2538. 10.1002/mds.28719
(2021). Progression in Parkinson’s disease: a potpourri of plots and probabilities. Brain, 3, 708–711. 10.1093/brain/awab060
(2021). Increased large vessel occlusive strokes following the Christchurch 2019 March 15 terror attack. Neurology, 96, 171-174. 10.1212/WNL.0000000000011341
2020
(2020). Microstructural integrity of the major nuclei of the thalamus in Parkinson’s disease. bioRxiv, 2020.05.21.1096. 10.1101/2020.05.21.109660
(2020). The impact of COVID‐19 on access to Parkinson’s disease medication. Movement Disorders. 10.1002/mds.28293
(2020). “Pervasive ocular tremor of Parkinson’s” is not pervasive, ocular, or uniquely parkinsonian. OSFPreprints. 10.31219/osf.io/s8rwt
(2020). Childbirth and delayed Parkinson’s onset: a reproducible non-biological artefact of societal change. Movement Disorders, 35, 1268-1271. 10.1002/mds.28135
(2020). Test-retest reliability and sample size estimates after MRI scanner relocation. Neuroimage 211, 116608. 10.1016/j.neuroimage.2020.116608
(2020). Cognitive tests that identify high risk of conversion to dementia in Parkinson's disease. bioRxiv, 2020.05.31.1268. 10.1101/2020.05.31.126870
2019
(2019). Volitional suppression of parkinsonian resting tremor. Movement Disorders Clinical Practice, 6, 470-478. 10.1002/mdc3.12801
(2019). Risk of Parkinson’s disease dementia related to level I MDS PD-MCI. Movement Disorders. 10.1002/mds.27617
(2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Frontiers in Neurology, 10, 391. 10.3389/fneur.2019.00391
(2019). Accelerating Electric Vehicle Uptake in New Zealand: an information gap analysis. Flip the Fleet Report No 4 (Comissioned report to Parliamentary Commissioner for the Environment / Te Kaitiaki Taiao a Te Whare Pāremata).
2018
(2018). Accelerated Reported Battery Capacity Loss in 30 kWh Variants of the Nissan Leaf. Preprints, 2018030122. 10.20944/preprints201803.0122.v1
(2018). Parkinson’s disease across ethnicities: a nation-wide study in New Zealand. Movement Disorders, 33, 1440-1448. 10.1002/mds.27389
2017
(2017). Construction of joint confidence regions for the optimal true class fractions of Receiver Operating Characteristic (ROC) surfaces and manifolds. Statistical Methods in Medical Research, 26, 1429-1442. 10.1177/0962280215581694
(2017). Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Movement Disorders, 32, 1056-1065. 10.1002/mds.27002
(2017). Caregiver burden is increased in Parkinson’s disease with mild cognitive impairment (PD-MCI). Translational Neurodegeneration, 6(17). 10.1186/s40035-017-0085-5
(2017). Parkinson's in the oldest old: Impact on estimates of future disease burden. Parkinsonism and Related Disorders, 42, 78-84. 10.1016/j.parkreldis.2017.06.018
2016
(2016). Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. Parkinsonism & Related Disorders, 22, 54-61. 10.1016/j.parkreldis.2015.11.008
(2016). Different PD-MCI criteria and risk of dementia in Parkinson’s disease: Four year longitudinal study. npj Parkinson's Disease, 2, 15027. 10.1038/npjparkd.2015.27
2015
(2015). Tracking Parkinson's disease over one year with multimodal magnetic resonance imaging in a group of older patients with moderate disease. PLOS ONE, 10, e0143923. 10.1371/journal.pone.0143923
2014
(2014). Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease dementia: an ASL-MRI study. Journal of Cerebral Blood Flow & Metabolism, 34, 964-970. 10.1038/jcbfm.2014.40
(2014). Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study. Translational Neurodegeneration, 3.
2013
(2013). "Ocular Tremor" in Parkinson’s Disease: A Technology-dependent Artifact of Universal Head Motion? Movement Disorders, 28, 1165-1166. 10.1002/mds.25602
(2013). Cross-Sectional Area of the Anterior Belly of the Digastric Muscle: Comparison of MRI and Ultrasound Measures. Dysphagia, 28, 375-380. 10.1007/s00455-012-9443-8
(2013). A perceptual discrimination task results in greater facilitation of voluntary saccades in Parkinson’s disease patients. European Journal of Neuroscience, 37(1), 163-172. 10.1111/ejn.12033
2012
(2012). The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson’s disease. Neuropsychologia, 50, 3338-3347. 10.1016/j.neuropsychologia.2012.09.025
2011
(2011). Pharyngeal pressures during swallowing within and across 3 sessions: within-subject variance and order effects. Dysphagia, 26, 385-391. 10.1007/s00455-010-9324-y
(2011). A perceptual discrimination task abnormally facilitates reflexive saccades in Parkinson's disease. European Journal of Neuroscience, 33, 2091-2100. 10.1111/j.1460-9568.2011.07697.x
2008
(2008). Design of a modular and low-latency virtual-environment platform for applications in motor adaptation research, neurological disorders, and neurorehabilitation. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 16, 298-309. r 10.1109/TNSRE.2008.922676
Abstracts and Short papers
2020
(2020). Will Flipping the Fleet F**k the Grid? ’ IAEE Asia-Oceania 2020: Energy in Transition. Auckland New Zealand.
(2020). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. MedRxiv, 2020, 09, 01, 20186312. https://doi.org/10.1101/2020.09.01.20186312
2018
(2018). Parkinsonian tremor can be diminished by willpower. Proceedings of the International Australasian Winter Conference on Brain Research, 36, 4.
(2018). Response to “Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms” [letter]. International Psychogeriatrics. 10.1017/S1041610218000091
2016
(2016). Risk of dementia in Parkinson’s disease: Towards optimal short cognitive testing. Proceedings of the 34th International Winter Conference on Brain Research, 1.
(2016). Amyloid imaging and cognition in Parkinson’s disease: Interim report. Proceedings of the 34th International Winter Conference on Brain Research, 3.
(2016). Epidemiology of Parkinson’s in New Zealand: Sex, age, and future burden. Proceedings of the 34th International Winter Conference on Brain Research, 34, 10, 4.
(2016). Ethnic and regional differences in Parkinson’s disease in New Zealand. Proceedings of the 34th International Winter Conference on Brain Research, 5.
2015
(2015). Longitudinal magnetic resonance spectroscopy in Parkinson’s disease. Proceedings of the 21st Annual Meeting of the Organization for Human Brain Mapping.
(2015). White matter lesions contribute to future dementia in Parkinson’s disease. Proceedings of the 21st Annual Meeting of the Organization for Human Brain Mapping.
2014
(2014). Cognitive status in Parkinsons disease characterised by magnetic resonance spectroscopy. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, 34.
(2014). White matter lesions - a factor in developing dementia in patients with Parkinsons disease. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, Abstract 3.5.
(2014). Individualised medicine: Predicting dementia in Parkinsons disease. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, Abstract 8.1.
(2014). Comparing mild cognitive impairment criteria in Parkinsons disease: influence on dementia onset. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, Abstract 6.4.
2013
(2013). Animal-naming in Parkinson's disease (Abstract). 2013 Neuroscience Meeting Planner San Diago, CA: Society for, 431, Program No.10/N5..
(2013). Tea with milk and sugar: gaze and action coordination in a real-world task in Parkinsons disease (Abstract). Proceedings of the 17th European Conference on Eye Movement Research, Lund, Journal of Eye Movement Research, 6(3), 512.
(2013). Progression in cognitive function of Huntington patients relative to controls: a 12 months study. Proceedings of the Movement Disorders Society 17th International Congress, Sydney, Movement Disorders, 28 Supplement 1, Abstract 760 .
(2013). Proceedings of the Movement Disorders Society 17th International Congress, Sydney, Movement Disorders, 28 Supplement 1, Abstract 758.
2012
(2012). Impairment of implicit prediction in rhythmic saccadic movement in symptomatic huntington patients (Abstract). Journal of Neurology, Neurosurgery, and Psychiatry, 83:Suppl 1, A34. 10.1136/jnnp-2012-303524.104
(2012). The effectiveness of cognitive and reflexive saccade measures in discriminating Huntingtons disease from healthy controls (Abstract). European Journal of Neurology, 19 Suppl 1, Poster 1661. 10.1111/j.1468-1331.2012.03888.x
2008
(2008). Submovements in visually-guided and memory-guided reaching tasks: changes in Parkinson’s disease. In Proceedings of the 30th Annual International Conference of IEEE Engineering in Medicine and Biology Society.